STENGONE CARMINE N. (CEO and President) sold 12.7% of their position (2.50K shares) of CONTINEUM THERAPEUTICS, INC. on the open market
Open‑market sale worth $41.1K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/8/2026ACC: 0001628280-26-060962
DirectorOfficer· CEO and President
Since Feb 2026
-2.50K
Net shares
Net seller
$41.1K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
2.50K acquired · 5K disposed
Non-Derivative Transactions2
Class A Common Stock
Direct
Shares
+2.50K
Price / share
$1.01
Trade value
$2.52K
% of position
14.5%
9/8/2026
17.22K→19.72K
Class A Common Stock
Direct
Shares
−2.50K
Price / share
$16.46
Trade value
$41.14K
% of position
12.7%
9/8/2026
19.72K→17.22K
Total
Net shares
+0.00
Net value
-$38.62K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 9/8/2026 | M · Option Exercise | +2.50K | $1.01 | $2.52K | 14.5% | 17.22K | 19.72K |
| Class A Common Stock Direct | 9/8/2026 | S · Sale | −2.50K | $16.46 | $41.14K | 12.7% | 19.72K | 17.22K |
| Total | +0.00 | -$38.62K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Class A Common Stock
2.50K shares
Shares
−2.50K
Strike price
1.01
Held after
274.43K
Exercisable
—
9/8/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Class A Common Stock2.50K shares | 9/8/2026 | M · Option Exercise | −2.50K | 1.01 | — | 274.43K |